Survival Pathways of HIF-Deficient Tumour Cells: TCA Inhibition, Peroxisomal Fatty Acid Oxidation Activation and an AMPK-PGC-1α Hypoxia Sensor

The HIF-1 and HIF-2 (HIF1/2) hypoxia responses are frequently upregulated in cancers, and HIF1/2 inhibitors are being developed as anticancer drugs. How could cancers resist anti-HIF1/2 therapy? We studied metabolic and molecular adaptations of HIF-1β-deficient Hepa-1c4, a hepatoma model lacking HIF...

Descripción completa

Detalles Bibliográficos
Autores principales: Golinska, Monika A., Stubbs, Marion, Harris, Adrian L., Boros, Laszlo G., Basetti, Madhu, McIntyre, Dominick J. O., Griffiths, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688062/
https://www.ncbi.nlm.nih.gov/pubmed/36429023
http://dx.doi.org/10.3390/cells11223595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688062/
https://www.ncbi.nlm.nih.gov/pubmed/36429023
http://dx.doi.org/10.3390/cells11223595

Ejemplares similares